about
Utility of interferon-gamma ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South AfricaCost-effectiveness of highly active antiretroviral therapy in South Africa.Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review.The impact of mass media interventions on tuberculosis awareness, health-seeking behaviour and health service utilisation: a systematic review protocol.Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patientsPublic-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland comparedScaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysisAntiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methodsScreening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective studyVirologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South AfricaRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirCost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South AfricaWhen to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern AfricaPoint-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysisCD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South AfricaDevelopment of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studiesAdolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa.Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African townshipCD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.Healthcare utilization of patients accessing an African national treatment program.Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited settingRisk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.Decreasing household contribution to TB transmission with age: a retrospective geographic analysis of young people in a South African townshipMortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings.Shared air: a renewed focus on ventilation for the prevention of tuberculosis transmission.Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling AnalysisVirologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysisLinkage to HIV care and antiretroviral therapy in Cape Town, South Africa.Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking systemAdjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa.Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa.Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration.Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme.Mortality after failure of antiretroviral therapy in sub-Saharan Africa.Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study.
P50
Q21261534-3A3AEC67-E2CA-46FB-A60C-D92D5BEE8C5DQ24814698-2BFD10B4-1BC6-449A-A858-0EAF7CA81935Q26824866-7E47466E-AD35-4742-A380-2BD3BF357455Q26829087-2C743CC1-F1E6-4D0C-B659-C73D93A7E4C9Q28249929-DEA08936-3F54-4222-B217-933BE530FC5EQ28473120-AA4A0B52-9343-4599-A54D-E8BAE220ABCFQ28476684-F92E8630-F6EB-4495-81E6-F6F176207716Q28478065-ADC2C1C6-52AE-4A0F-A354-2D3A918D5877Q28479309-14FF8C2E-163D-4A96-A577-0AD33A72A216Q28481468-8029E5F0-3B43-4C52-93E6-F339902F59A0Q28533242-E199A914-C282-4F7E-9889-EF91217A2E44Q28534733-878595D4-42C0-4694-A5B7-EB73A5E9FE9FQ28535251-60BAB3D7-571F-49D7-ACD6-3D71D64A9CF5Q28543954-CBA880DC-70AA-43A2-8E91-474ADEBBFFDAQ28703565-C9D127F4-EF65-4ABF-AB78-A8BDBCA95820Q28743478-F89567D6-262F-4CB3-A2EE-69335558EF13Q30228870-BD64109A-F4AF-469B-981C-DACC19405786Q30773592-A2CF6370-7146-4737-B0A4-927810763E29Q33237178-26434FC6-5F2D-4A75-A5FD-FB39896B5574Q33284948-EA02D064-60A4-44FC-B72E-FC12876BC4AAQ33287043-F81D37F8-C7EA-4065-9A63-3FC2E5E68ACAQ33349204-0EC451A8-0DBA-4349-BE2A-1003417D2A48Q33352323-A4D8B56D-CCAF-4FA1-9FB1-6625B5CA1D27Q33574194-2A9D48CA-D3B6-4BA2-8705-C628FF9683D9Q33574798-C895319F-9620-44E9-9CC5-5C932FC40206Q33576031-42C75EE5-8164-415E-A053-EF7BA9BD3EC3Q33577939-8EBFE7CE-90B2-4EE0-ACFB-98614B692F25Q33619587-E2C38E24-A5BA-48EF-AC3D-9B764590D8B5Q33624953-D1FA3E10-1023-4F0B-8CF3-F38142F20A57Q33745099-1782AB66-567A-4219-99B9-3C2DFF4D6AA0Q33746982-154A0F10-CEB3-406A-B4D5-397E30F4416BQ33770158-3E3D8F89-A502-405E-955C-69FFA5551843Q33803701-94519256-D0F9-408A-93AB-AAAADD013A9CQ33830775-4C815D20-65A7-48C9-8F63-B940FC7153C3Q33851741-DFE2C921-709D-4FBF-A17D-91546CEB7638Q33854505-E9C30AF1-81AF-444D-B621-F42B3826B39BQ33858110-E41EC9F1-BA49-4EC2-AD3D-0C90D3BAF3FEQ33862806-BBE8706C-70E8-4E63-A2AB-15CD0B5B7F2EQ33871884-24941C11-7EEC-494B-B843-E55A4A0AF4DBQ33919181-90AB5E49-3A66-4C1D-8391-5FC6A4372BBD
P50
name
Robin Wood
@ast
Robin Wood
@en
Robin Wood
@es
Robin Wood
@nl
type
label
Robin Wood
@ast
Robin Wood
@en
Robin Wood
@es
Robin Wood
@nl
prefLabel
Robin Wood
@ast
Robin Wood
@en
Robin Wood
@es
Robin Wood
@nl